Note 4 - Acquisitions (Details Textual)

Note 4 - Acquisitions (Details Textual) - USD ($) $ in Thousands			3 Months Ended
	Aug. 01, 2018	Jul. 02, 2018	Sep. 30, 2018	Sep. 30, 2017
Payments to Acquire Businesses, Net of Cash Acquired, Total			$ 272,229	$ 10,634
QT Holdings Corporation [Member]
Payments to Acquire Businesses, Net of Cash Acquired, Total		$ 20,404
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High		$ 51,000	51,000
QT Holdings Corporation [Member] \| Developed Technology Rights [Member]
Finite-Lived Intangible Asset, Useful Life		15 years
Exosome Diagnostics, Inc [Member]
Payments to Acquire Businesses, Net of Cash Acquired, Total	$ 251,800	$ 251,825
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	325,000		$ 325,000
Exosome Diagnostics, Inc [Member] \| Calendar Year 2020 EBITA Between $45 Million and $58 Million or Greater [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	250,000
Exosome Diagnostics, Inc [Member] \| Calendar Year 2022 EBITA for A New Instrument Product Between $54 Million and $70 Million or Greater [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	45,000
Exosome Diagnostics, Inc [Member] \| Calendar Year 2022 EBITA for Remaining Business Between $150 Million and $190 Million or Greater [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	$ 30,000
Exosome Diagnostics, Inc [Member] \| Developed Technology Rights [Member]
Finite-Lived Intangible Asset, Useful Life	15 years

Quarterly report pursuant to Section 13 or 15(d)

Note 4 - Acquisitions (Details Textual)